The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC).
 
Jennifer Wilkinson Carlisle
No Relationships to Disclose
 
Nhu Thi Nho
No Relationships to Disclose
 
Chaejin Kim
No Relationships to Disclose
 
Zhengjia Chen
No Relationships to Disclose
 
Shiyong Li
No Relationships to Disclose
 
Charles Hill
No Relationships to Disclose
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Takeda
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Gabriel Sica
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Eisai; Eisai; G1 Therapeutics; Lilly; MedImmune; Novartis; Sandoz; Seagen; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)